probucol has been researched along with Albuminuria in 11 studies
Probucol: A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993).
probucol : A dithioketal that is propane-2,2-dithiol in which the hydrogens attached to both sulfur atoms are replaced by 3,5-di-tert-butyl-4-hydroxyphenyl groups. An anticholesteremic drug with antioxidant and anti-inflammatory properties, it is used to treat high levels of cholesterol in blood.
Albuminuria: The presence of albumin in the urine, an indicator of KIDNEY DISEASES.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine the effect of probucol on urine albumin excretion in type 2 diabetes mellitus patients with albuminuria using angiotensin-converting enzyme inhibitors or angiotensin receptor blockers." | 5.22 | Probucol in Albuminuric Type 2 Diabetes Mellitus Patients on Renin-Angiotensin System Blockade: A 16-Week, Randomized, Double-Blind, Placebo-Controlled Trial. ( Baik, SH; Cha, BS; Choi, SH; Chung, CH; Han, KA; Hwang, YC; Jin, SM; Ko, SH; Lee, HW; Lee, IK; Lee, MK; Nam, MS; Park, IeB; Park, TS; Rhee, EJ; Sohn, TS; Yu, JM, 2016) |
| "The pathogenesis of antiphospholipid antibody (aPL) related thrombosis is multifactorial and includes, amongst others, enhanced coagulation activation measured as prothrombin fragment 1 + 2 (F1 + 2), elevated plasma levels of von Willebrand factor (vWF), plasminogen activator inhibitor (PAI) and endothelin-1 (ET-1) as well as heightened thromboxane generation and lipid peroxidation." | 5.09 | Antioxidant susceptibility of pathogenic pathways in subjects with antiphospholipid antibodies: a pilot study. ( Alves, J; Ames, PR; Brancaccio, V; Caccavo, F; Caruso, S; Fossati, G; Iannaccone, L; Morrow, JD; Tommasino, C, 2000) |
| "Probucol has antioxidant as well as cholesterol-lowering effects." | 2.78 | Probucol suppresses initiation of chronic hemodialysis therapy and renal dysfunction-related death in diabetic nephropathy patients: Sakura study. ( Ban, N; Endo, K; Kawana, H; Miyashita, Y; Murano, T; Nagayama, D; Nagumo, A; Ohira, M; Oyama, T; Saiki, A; Sakuma, K; Sasaki, H; Shirai, K; Suzuki, Y; Tatsuno, I; Yamaguchi, T; Yamamura, S, 2013) |
| "Probucol has antioxidant and cholesterol-lowering effects." | 2.72 | Probucol delays progression of diabetic nephropathy. ( Endo, K; Ito, Y; Koide, N; Miyashita, Y; Ohira, M; Otsuka, M; Oyama, T; Saiki, A; Sasaki, H; Shirai, K; Takeyoshi, M, 2006) |
| "Probucol has a more pronounced health benefit than high-dose CoQ(10) supplementation and uniquely restores CoQ(9) content in mutant kidney." | 1.37 | Probucol ameliorates renal and metabolic sequelae of primary CoQ deficiency in Pdss2 mutant mice. ( Chen, JY; Clarke, CF; Falk, MJ; Gasser, DL; Horyn, O; King, R; Maltzman, JS; Marbois, B; Nakamaru-Ogiso, E; Nissim, I; Okwuego, E; Ostrovsky, J; Peng, M; Polyak, E; Xie, LX; Zhang, Z, 2011) |
| "Focal segmental glomerulosclerosis is a steroid-resistant glomerular disease characterized by foot process flattening and heavy proteinuria." | 1.30 | Glomerular overproduction of oxygen radicals in Mpv17 gene-inactivated mice causes podocyte foot process flattening and proteinuria: A model of steroid-resistant nephrosis sensitive to radical scavenger therapy. ( Binder, CJ; Exner, M; Kerjaschki, D; Weiher, H, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (18.18) | 18.2507 |
| 2000's | 4 (36.36) | 29.6817 |
| 2010's | 5 (45.45) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhou, G | 1 |
| Wang, Y | 1 |
| He, P | 2 |
| Li, D | 1 |
| Jin, SM | 1 |
| Han, KA | 1 |
| Yu, JM | 1 |
| Sohn, TS | 1 |
| Choi, SH | 1 |
| Chung, CH | 1 |
| Park, IeB | 1 |
| Rhee, EJ | 1 |
| Baik, SH | 1 |
| Park, TS | 1 |
| Lee, IK | 1 |
| Ko, SH | 1 |
| Hwang, YC | 1 |
| Cha, BS | 1 |
| Lee, HW | 1 |
| Nam, MS | 1 |
| Lee, MK | 1 |
| Kawamura, H | 1 |
| Takemoto, M | 1 |
| Maezawa, Y | 1 |
| Ishikawa, T | 1 |
| Ishibashi, R | 1 |
| Sakamoto, K | 1 |
| Shoji, M | 1 |
| Hattori, A | 1 |
| Yamaga, M | 1 |
| Ide, S | 1 |
| Ide, K | 1 |
| Hayashi, A | 1 |
| Tokuyama, H | 1 |
| Kobayashi, K | 1 |
| Yokote, K | 1 |
| Falk, MJ | 1 |
| Polyak, E | 1 |
| Zhang, Z | 1 |
| Peng, M | 1 |
| King, R | 1 |
| Maltzman, JS | 1 |
| Okwuego, E | 1 |
| Horyn, O | 1 |
| Nakamaru-Ogiso, E | 1 |
| Ostrovsky, J | 1 |
| Xie, LX | 1 |
| Chen, JY | 1 |
| Marbois, B | 1 |
| Nissim, I | 1 |
| Clarke, CF | 1 |
| Gasser, DL | 1 |
| Endo, K | 2 |
| Saiki, A | 2 |
| Yamaguchi, T | 1 |
| Sakuma, K | 1 |
| Sasaki, H | 2 |
| Ban, N | 1 |
| Kawana, H | 1 |
| Nagayama, D | 1 |
| Nagumo, A | 1 |
| Ohira, M | 2 |
| Oyama, T | 2 |
| Murano, T | 1 |
| Miyashita, Y | 2 |
| Yamamura, S | 1 |
| Suzuki, Y | 1 |
| Shirai, K | 2 |
| Tatsuno, I | 1 |
| Koide, N | 1 |
| Otsuka, M | 1 |
| Takeyoshi, M | 1 |
| Ito, Y | 1 |
| Yoshida, M | 1 |
| Kimura, H | 1 |
| Kyuki, K | 1 |
| Ito, M | 1 |
| Soulis-Liparota, T | 1 |
| Cooper, ME | 1 |
| Dunlop, M | 1 |
| Jerums, G | 1 |
| Binder, CJ | 1 |
| Weiher, H | 1 |
| Exner, M | 1 |
| Kerjaschki, D | 1 |
| Ames, PR | 1 |
| Tommasino, C | 1 |
| Alves, J | 1 |
| Morrow, JD | 1 |
| Iannaccone, L | 1 |
| Fossati, G | 1 |
| Caruso, S | 1 |
| Caccavo, F | 1 |
| Brancaccio, V | 1 |
| Nishimura, M | 1 |
| Sasaki, T | 1 |
| Ohishi, A | 1 |
| Oishi, M | 1 |
| Kono, S | 1 |
| Totani, Y | 1 |
| Kato, Y | 1 |
| Noto, Y | 1 |
| Misaki, S | 1 |
| Higashi, K | 1 |
| Shimada, F | 1 |
| Wakasugi, H | 1 |
| Inoue, K | 1 |
| Hoshiyama, Y | 1 |
| Yamada, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II, Multicenter, Randomized, Double Blind, Double-dummy, 16-week, Placebo Controlled Study to Evaluate the Efficacy and Safety of Probucol in Patients With Nephropathy Due to Type 2 Diabetes.[NCT01726816] | Phase 2 | 126 participants (Actual) | Interventional | 2012-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 trials available for probucol and Albuminuria
| Article | Year |
|---|---|
Probucol in Albuminuric Type 2 Diabetes Mellitus Patients on Renin-Angiotensin System Blockade: A 16-Week, Randomized, Double-Blind, Placebo-Controlled Trial.
Topics: Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inh | 2016 |
Probucol suppresses initiation of chronic hemodialysis therapy and renal dysfunction-related death in diabetic nephropathy patients: Sakura study.
Topics: Aged; Albuminuria; Anticholesteremic Agents; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Creati | 2013 |
Probucol delays progression of diabetic nephropathy.
Topics: Aged; Albuminuria; Anticholesteremic Agents; Blood Pressure; Cholesterol; Cholesterol, HDL; Creatini | 2006 |
Antioxidant susceptibility of pathogenic pathways in subjects with antiphospholipid antibodies: a pilot study.
Topics: Adult; Albuminuria; Antibodies, Antiphospholipid; Anticholesteremic Agents; Anticoagulants; Antioxid | 2000 |
Angiotensin-converting enzyme inhibitors and probucol suppress the time-dependent increase in urinary Type IV collagen excretion of Type II diabetes mellitus patients with early diabetic nephropathy.
Topics: Acetylglucosaminidase; Adult; Aged; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antioxida | 2001 |
6 other studies available for probucol and Albuminuria
| Article | Year |
|---|---|
Probucol inhibited Nox2 expression and attenuated podocyte injury in type 2 diabetic nephropathy of db/db mice.
Topics: Albuminuria; Animals; Antioxidants; Collagen Type IV; Diabetes Mellitus, Type 2; Disease Models, Ani | 2013 |
Combination of cilostazol and probucol protected podocytes from lipopolysaccharide-induced injury by both anti-inflammatory and anti-oxidative mechanisms.
Topics: Albuminuria; Animals; Anti-Inflammatory Agents; Antioxidants; Cells, Cultured; Chemokine CCL2; Cilos | 2017 |
Probucol ameliorates renal and metabolic sequelae of primary CoQ deficiency in Pdss2 mutant mice.
Topics: Albuminuria; Alkyl and Aryl Transferases; Animals; Anticholesteremic Agents; Antioxidants; Energy Me | 2011 |
Combined effect of probucol and insulin on renal damage in diabetic rats fed a high cholesterol diet.
Topics: Albuminuria; Animals; Anticholesteremic Agents; Antioxidants; Blood Glucose; Cholesterol; Cholestero | 2006 |
The relative roles of advanced glycation, oxidation and aldose reductase inhibition in the development of experimental diabetic nephropathy in the Sprague-Dawley rat.
Topics: Albuminuria; Aldehyde Reductase; Animals; Antioxidants; Blood Glucose; Body Weight; Butylated Hydrox | 1995 |
Glomerular overproduction of oxygen radicals in Mpv17 gene-inactivated mice causes podocyte foot process flattening and proteinuria: A model of steroid-resistant nephrosis sensitive to radical scavenger therapy.
Topics: Aging; Albuminuria; Animals; Disease Models, Animal; Free Radical Scavengers; Glomerulosclerosis, Fo | 1999 |